RxDoctor Payments Data

Jason Leffew

Critical Care Medicine · Kettering, OHNPI 1891342085

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Bayer at 39.1% of the total.

$1,109in general payments, 2019–2025

Across 49 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$434
  • Mylan Specialty L.p.$190
  • Eisai Inc.$78
  • Lilly USA, LLC$65
  • Teva Pharmaceuticals USA, Inc.$52
  • Sumitomo Pharma America, Inc.$46
  • plus $244 from 10 others

What the payments were for

  • Food & beverage$1,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,109 in reported general payments places this provider in the 80th percentile of 285 critical care medicine providers in Ohio.

See all critical care medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$65,042
Medicare patients
154
Services billed
794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide18$18,603
FarxigaDapagliflozin Propanediol56$16,600
EliquisApixaban41$11,824
Breo ElliptaFluticasone/Vilanterol16$6,972
Gabapentin421$6,882
Fentanyl24$3,689
JardianceEmpagliflozin11$3,353
DapagliflozinDapagliflozin Propanediol13$3,277
MyrbetriqMirabegron13$2,993
Pantoprazole Sodium74$1,624
Mirtazapine49$1,449
PremarinEstrogens, Conjugated13$1,375
LokelmaSodium Zirconium Cyclosilicate12$1,248
Duloxetine Hcl37$1,210
Potassium Chloride39$1,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$65$18,60318 claims
PfizerEliquis, Premarin$24$13,19954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 285 critical care medicine providers in Ohio.

Other critical care medicine in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →